Miricor Enterprises Holdings (HKSE:01827) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01827 Miricor Enterprises Holdings Ltd HKSE:01827
62 GF Score
Price HK$0.87
GF Value HK$0.91
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Miricor Enterprises Holdings FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01827
62GF Score
Miricor Enterprises Holdings Ltd HKSE:01827
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Miricor Enterprises Holdings (HKSE:01827) Overvalued in 2026?

Based on GuruFocus' analysis, Miricor Enterprises Holdings stock appears to be undervalued. The current stock price of HK$0.87 is trading 4.4% below its estimated GF Value™ of HK$0.91. GuruFocus considers Miricor Enterprises Holdings to be Fairly Valued.

Key valuation signals for HKSE:01827:

  • FFO:
  • GF Value™: HK$0.91 vs. price of HK$0.87 (4.4% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the HKSE:01827 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Miricor Enterprises Holdings Business Description

Address 88 Connaught Road Central, 18th Floor, Nan Fung Tower, Central, Hong Kong, HKG
Miricor Enterprises Holdings Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the provision of medical aesthetic services and the sale of skin care products. The group's only reportable operating segment is the non-surgical medical aesthetic and wellness beauty services segment, and is principally engaged in the provision of medical aesthetic services and the sale of skin care products in Hong Kong and Mainland China. The majority of its revenue is generated from the provision of treatment services. Geographically, the group derives maximum revenue from Hong Kong.
62GF Score

Get the complete analysis for HKSE:01827

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.87
Price
HK$0.91
GF Value